Thomas P
Pôle de psychiatrie, médecine légale et médecine en milieu pénitentiaire, Université Lille Nord de France, CHRU Lille, Hôpital Fontan, rue André-Verhaeghe, F-59037 Lille cedex, France.
Encephale. 2013 Sep;39 Suppl 2:S79-82. doi: 10.1016/S0013-7006(13)70100-3.
Relapse after a first episode of schizophrenia is the recurrence of acute symptoms after a period of partial or complete remission. Due to its variable aspects, there is no operational definition of relapse able to modelise the outcome of schizophrenia and measure how the treatment modifies the disease. Follow-up studies based on proxys such as hospital admission revealed that 7 of 10 patients relapsed after a first episode of schizophrenia. The effectiveness of antipsychotic medications on relapse prevention has been widely demonstrated. Recent studies claim for the advantages of atypical over first generation antipsychotic medication. Non-adherence to antipsychotic represents with addictions the main causes of relapse long before some non-consensual factors such as premorbid functioning, duration of untreated psychosis and associated personality disorders. The consequences of relapse are multiple, psychological, biological and social. Pharmaco-clinical studies have demonstrated that the treatment response decreases with each relapse. Relapse, even the first one, will contribute to worsen the outcome of the disease and reduce the capacity in general functionning. Accepting the idea of continuing treatment is a complex decision in which the psychiatrist plays a central role besides patients and their families. The development of integrated actions on modifiable risk factors such as psychosocial support, addictive comorbidities, access to care and the therapeutic alliance should be promoted. Relapse prevention is a major goal of the treatment of first-episode schizophrenia. It is based on adherence to the maintenance treatment, identification of prodromes, family active information and patient therapeutical education.
精神分裂症首次发作后的复发是指在一段部分或完全缓解期后急性症状的再次出现。由于其具有多种不同方面,目前尚无能够模拟精神分裂症预后并衡量治疗如何改变疾病的复发操作性定义。基于诸如住院等替代指标的随访研究显示,10名精神分裂症首次发作患者中有7人会复发。抗精神病药物在预防复发方面的有效性已得到广泛证实。近期研究表明非典型抗精神病药物优于第一代抗精神病药物。在一些存在争议的因素(如病前功能、未治疗精神病的持续时间和相关人格障碍)出现之前很久,不坚持服用抗精神病药物和成瘾就是复发的主要原因。复发的后果是多方面的,包括心理、生物和社会方面。药物临床研究表明,每次复发后治疗反应都会降低。复发,即使是首次复发,也会导致疾病预后恶化并降低总体功能能力。接受持续治疗的想法是一个复杂的决定,在这个过程中,除了患者及其家属外,精神科医生起着核心作用。应推动针对可改变风险因素开展综合行动,如心理社会支持、成瘾共病、获得治疗的机会以及治疗联盟。预防复发是首次发作精神分裂症治疗的主要目标。它基于坚持维持治疗、识别前驱症状、向家庭提供积极信息以及对患者进行治疗教育。